

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. DOX 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/073,203	02/13/2002	Hartmut Strobel	04734.0005	5292	
75	590 05/27/2003				
Finnegan, Henderson, Farabow,			EXAMINER		
Garrett & Dunn 1300 I Street, N	•		KIFLE, BRUCK		
Washington, DC 20005-3315			ART UNIT	PAPER NUMBER	
			1624	1624	
			DATE MAILED: 05/27/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.



# Office Action Summary

Application No. 10/073,203

Applicant(s)

Strobel et al.

Examiner

Bruck Kifle, Ph.D.

Art Unit 1624

	The MAILING DATE of this communication appears	on the cover she	eet with	the correspondence address		
	for Reply					
	ORTENED STATUTORY PERIOD FOR REPLY IS SET	TO EXPIRE	3	MONTH(S) FROM		
	MAILING DATE OF THIS COMMUNICATION. sions of time may be available under the provisions of 37 CFR 1.136 (a). In	no event, however, m	nav a reply	he timely filed after SIX (6) MONTHS from the		
mailing	g date of this communication.					
- If NO p	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply a	and will expire SIX (6)	MONTHS :	from the mailing date of this communication.		
- Any re	e to reply within the set or extended period for reply will, by statute, cause the eply received by the Office later than three months after the mailing date of t					
_	d patent term adjustment. See 37 CFR 1.704(b).					
Status 1) 💢	Responsive to communication(s) filed on Feb 13, 2	2002		·		
2a) 🗌	This action is <b>FINAL</b> . 2b) 💢 This act					
3) 🗆	☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposi	ition of Claims					
4) 💢	Claim(s) <u>1-23</u>			is/are pending in the application.		
4	4a) Of the above, claim(s) 7-21			is/are withdrawn from consideration.		
5) 🗆	Claim(s)			is/are allowed.		
6) 💢	Claim(s) <u>1-6, 22, and 23</u>			is/are rejected.		
7) 🗆	Claim(s)			is/are objected to.		
8) 🗆	Claims	are	subject	t to restriction and/or election requirement.		
Applica	ation Papers					
9) 🗆	The specification is objected to by the Examiner.					
10)	The drawing(s) filed on is/are	; a) 🗆 accepter	d or b)	$\square$ objected to by the Examiner.		
	Applicant may not request that any objection to the di					
11)	The proposed drawing correction filed on	is:	a) 🗆 🔞	approved b) $\square$ disapproved by the Examiner.		
	If approved, corrected drawings are required in reply t	to this Office act	tion.			
12) 🗌	2) The oath or declaration is objected to by the Examiner.					
Priority	under 35 U.S.C. §§ 119 and 120					
13)💢	13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) 🗴	All b) □ Some* c) □ None of:			1		
,	1. X Certified copies of the priority documents have been received.					
:	2.   Certified copies of the priority documents have	re been received	d in Apr	plication No		
;	3. Copies of the certified copies of the priority do application from the International Burea	ocuments have	been re	eceived in this National Stage		
*Se	ee the attached detailed Office action for a list of the					
	_					
a) The translation of the foreign language provisional application has been received.						
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)  1) X Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413) Paper No(s)						
	otice of References Cited (PTO-892) stice of Draftsperson's Patent Drawing Review (PTO-948)	_				
	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	5) Notice of Informal Petent Application (PTO-152) 6) Other:				
A. M.	Amation Discostile Statement(s) (F10-1445) Paper (40(s).	o) Uther:				

#### Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-6, 22 and 23, drawn to compounds of formula I and their pharmaceutical compositions, classified in classes 540, 544, 546, 548 and 564, various subclasses.
- II. Claims 7-13, drawn to a method of stimulating the expression of endothelial NOsynthase in a mammal, classified in class 514, subclass 183+, 613+, etc.
- III. Claims 14-21, drawn to a method of treating diseases recited in claim 14, classified in class 514, subclass 183+, 613+, etc.

The inventions are distinct, each from the other because of the following reasons: Groups I and II-III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the diseases embraced by the method of use claims are known to be treated by other compounds.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and because the search required for Group I is not required for Groups II and III, restriction for examination purposes as indicated is proper.

Application/Control Number: 10/073,203 Page 3

Art Unit: 1624

During a telephone conversation with Ms. Wang on May 20, 2003 a provisional election was made with traverse to prosecute the invention of group I, claims 1-6, 22 and 23. Affirmation of this election must be made by applicant in replying to this Office action. Claims 7-21 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

### Claim Rejections - 35 USC § 112

Claims 1-6, 22 and 23 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. In claim 1, the phrase "An acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amine according to the general formula (I)" renders the claim indefinite because one cannot say what else is intended. The phrase "A compound of formula (I)" is suggested as this term along with the structural formula and definitions of the variables fully defines the compound.

Art Unit: 1624

Claim 22 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 23. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k).

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vejdelek et al. (Collection of Czechoslovak Chemical Communications (1971), 36(4), 1611-23). The reference teaches the compound of RN 35047-56-4. The claims differ by requiring the -NH-C(O)-R<sup>5</sup> group at the 2-position over the 1-position of the prior art compound. Compounds that differ only by the position of the ring substituent are ring position isomers.

Position isomers are well established as being prima facie structurally obvious. See:

Ex parte Engelhardt, 208 USPQ 343, 349; In re Mehta, 146 USPQ 284; In re Surrey, 138 USPQ
67; Ex parte Ullyot 103 USPQ 185; Ex parte Naito 168 USPQ 437, 439; In re Norris 84 USPQ
459; Ex parte Allais 152 USPQ 66; Ex parte Henkel 130 USPQ 474; Ex parte Biel 124 USPQ

Application/Control Number: 10/073,203 Page 5

Art Unit: 1624

109; In re Crownse 150 USPQ 554; In re Fouche 169 USPQ 431; Ex parte Ruddy 121 USPQ 427; In re Wiechert 152 USPQ 249.

For example "Position Isomerism has been used as a tool to obtain new and useful drugs" (Engelhardt), and Position isomerism is a fact of close <u>structural</u> similarity" (Mehta, emphasis in the original).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruck Kifle whose telephone number is (703) 305-4484.

The fax phone number for this Group is (703) 308-4556 or (703) 305-3592. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

May 22, 2003

Primary Examiner
Art Unit 1624